Zura Bio LTD

Zura Bio Limited has released an updated corporate presentation detailing its lead drug candidate, tibulizumab, and its ongoing clinical trials for complex immune disorders.

Zura Bio Limited shareholders approved an amended equity incentive plan and elected directors at the company's Annual General Meeting.

Zura Bio announced first quarter 2026 financial results, highlighting progress in its Phase 2 studies for tibulizumab and a strengthened financial position.

Zura Bio announces the departure of CFO Eric Hyllengren and the appointment of Marlyn Mathew as his successor.

Zura Bio Limited announced its full fiscal year 2025 financial results and provided updates on its clinical programs, including a strengthened balance sheet and anticipated Phase 2 data readouts.

Zura Bio Limited announced it will present the design of its ongoing Phase 2 TibuSURE clinical trial for systemic sclerosis at the 9th Systemic Sclerosis World Congress.

Zura Bio reports a significant increase in R&D expenses for Q1 2026, driven by ongoing clinical trials, while maintaining a robust cash position following a recent equity offering.

Zura Bio Limited reported increased R&D expenses for its lead product candidates and a higher net loss for the nine months ended September 30, 2025, while maintaining liquidity through 2027.

Zura Bio Limited reported a significant increase in net losses for the second quarter and first half of 2025, driven by higher research and development and general and administrative expenses, while advancing its lead product candidates into Phase 2 clinical trials.

Zura Bio Limited reports a net loss for Q1 2025 while advancing its clinical-stage product candidates and evaluating development opportunities.

Zura Bio Limited released its third quarter 2024 financial results, showcasing advancements in its clinical programs and a strengthened financial position.

Zura Bio Limited, a clinical-stage biotechnology company, released its financial results for the second quarter of 2024, highlighting a decrease in research and development expenses and a recent warrant exchange.

Zura Bio Limited, a clinical-stage biotechnology company, reported a net loss of $68.7 million for the fiscal year ended December 31, 2025, while successfully raising $135.1 million in a February 2026 equity offering to fund ongoing clinical trials.

Zura Bio Limited details its financial performance for 2024 and provides updates on its clinical-stage immunology programs, including the initiation of a Phase 2 study for tibulizumab in systemic sclerosis.

Zura Bio Limited outlines its share capital, including Class A Ordinary Shares, preference shares, and details of outstanding warrants in a recent SEC filing.

Zura Bio Ltd reports the grant of employee stock options to Chief Technology Officer Gary Whale, with vesting conditions tied to continuous service.

Zura Bio Ltd reports on an executive's stock option grant, detailing vesting schedules and beneficial ownership.

Zura Bio Ltd reports that Chief Financial Officer Eric J. Hyllengren was granted employee stock options on April 1, 2026.

Zura Bio Ltd. reports the grant of employee stock options to Chief Legal Officer Kim Davis, with vesting over several years.

Sandeep Kulkarni, CEO of Zura Bio Ltd., has acquired stock options for 894,000 shares, with vesting scheduled to begin in April 2027.

Zura Bio Ltd. Director Ajay Nirula was granted 37,812 stock options with an exercise price of $6.53, vesting over one year starting February 21, 2026.

Zura Bio Limited has issued its proxy statement for the 2026 Annual General Meeting to be held virtually on June 17, 2026.

Zura Bio Limited is holding its annual general meeting on May 21, 2025, to elect directors, ratify the appointment of its auditor, and approve a proposal for adjournment if necessary.

Zura Bio Limited will hold its Annual General Meeting virtually on October 23, 2024, seeking shareholder votes on director elections, auditor ratification, and potential meeting adjournment.

Zura Bio Limited announces its annual general meeting of shareholders to be held virtually on October 23, 2024, to vote on the election of directors, ratification of the accounting firm, and approval of adjournment if necessary.

Zura Bio Limited has filed a registration statement for the resale of up to 41,596,750 Class A Ordinary Shares by selling securityholders.

AI Biotechnology LLC, an entity controlled by Len Blavatnik, increased its beneficial ownership in Zura Bio Limited to 18.2% through a recent share purchase and warrant holdings.

Athanor Capital and UGS Capital LLC report a 15.7% beneficial ownership in Zura Bio Limited, with a director from the group re-appointed to the board.

Access Industries affiliates, including AI Biotechnology LLC and Len Blavatnik, have increased their beneficial ownership in Zura Bio Limited to 19.9% through a series of share and warrant transactions.

Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly filed a Schedule 13G, reporting beneficial ownership of 4,215,930 Class A Ordinary Shares of Zura Bio Limited, representing 4.44% of the class.

Suvretta Capital Management and Aaron Cowen report a 9.9% beneficial ownership stake in Zura Bio Limited via Schedule 13G filing.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Zura Bio Ltd.'s Class A Ordinary Shares as of April 30, 2026.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen report continued significant beneficial ownership in Zura Bio Limited's Class A Ordinary Shares.

Athanor Capital and UGS Capital LLC jointly reported a 15.7% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, reported a 5.87% beneficial ownership stake in Zura Bio Ltd's Class A Ordinary Shares.